Hospital
Aspirus Medford Hospital & Clinics, INC.
Aspirus Medford Hospital & Clinics, INC. was paid $11.83M by Medicaid between Jan 2018 and Dec 2024, across 158 billing codes. Its largest line is 99283, emergency room visit (moderate) — 23% of everything it billed.
33Billing provider infoASPIRUS MEDFORD HOSPITAL & CLINICS, INC.
MEDFORD, WI 54451
MEDFORD, WI 54451
33aNPI1619079597assigned 09/02/2006
33bProvider typeCritical Access Hospital
28Total paid$11.83M
24GClaims229,994
24DCodes billed158
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Wisconsin
Rank by total paid#5 of 48
Median peer was paid$4.30M
This provider vs. median2.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official YANG, JERRY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 24,977 | $946K | |
| 2019 | 29,274 | $1.17M | |
| 2020 | 26,805 | $1.40M | |
| 2021 | 36,817 | $1.47M | |
| 2022 | 36,360 | $1.95M | |
| 2023 | 39,251 | $2.39M | |
| 2024incomplete | 36,510 | $2.51M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 23% | 17,883 | 15,069 | $2.73M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 15% | 11,871 | 9,747 | $1.83M |
| 96361 | Intravenous infusion, hydration; each additional hour | 13% | 2,977 | 2,399 | $1.50M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 12% | 7,106 | 6,134 | $1.38M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.9% | 3,713 | 3,006 | $822K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 4.0% | 1,960 | 1,347 | $473K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.7% | 1,189 | 900 | $316K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.3% | 3,006 | 2,391 | $278K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 2.3% | 2,840 | 2,455 | $270K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.1% | 1,137 | 769 | $246K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 1.5% | 1,043 | 794 | $180K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.1% | 1,371 | 813 | $125K |
146 more codes
| 80053 | Comprehensive metabolic panel | <1% | 13,203 | $106K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 479 | $101K |
| 93976 | <1% | 468 | $78K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 14,703 | $76K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,822 | $76K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 4,657 | $64K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,782 | $64K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,776 | $61K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 874 | $55K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 152 | $47K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 333 | $46K |
| 80061 | Lipid panel | <1% | 3,738 | $43K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,271 | $42K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 362 | $41K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 310 | $36K |
| 87070 | <1% | 3,655 | $35K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 385 | $35K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,378 | $33K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 758 | $31K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 542 | $27K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 72 | $27K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 173 | $26K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 5,658 | $25K |
| 81025 | <1% | 2,668 | $25K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,017 | $23K |
| 81001 | <1% | 8,360 | $23K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,626 | $23K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,287 | $22K |
| 84484 | <1% | 3,385 | $20K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 717 | $20K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,554 | $19K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 694 | $19K |
| 85027 | <1% | 3,174 | $15K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,942 | $15K |
| 76801 | <1% | 107 | $14K | |
| 87088 | <1% | 2,153 | $13K | |
| 83690 | <1% | 2,485 | $12K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,178 | $12K |
| 80306 | <1% | 944 | $12K | |
| 83735 | <1% | 3,236 | $12K | |
| 71045 | Radiologic examination, chest; single view | <1% | 5,094 | $11K |
| 74019 | <1% | 452 | $10K | |
| 87077 | <1% | 1,296 | $9K | |
| 84439 | <1% | 1,267 | $9K | |
| 86140 | <1% | 2,314 | $8K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,339 | $7K |
| 85610 | <1% | 2,408 | $7K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,198 | $7K |
| 83880 | <1% | 396 | $7K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 4,577 | $6K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 36 | $6K |
| 96367 | <1% | 18 | $6K | |
| 87186 | <1% | 955 | $6K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 39 | $6K |
| 84703 | <1% | 831 | $6K | |
| G0378 | Hospital observation service, per hour | <1% | 75 | $5K |
| 86850 | <1% | 818 | $5K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 17 | $5K |
| 73630 | <1% | 156 | $5K | |
| 76830 | Ultrasound, transvaginal | <1% | 32 | $4K |
| 85379 | <1% | 717 | $4K | |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 157 | $4K |
| 83605 | <1% | 720 | $4K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 423 | $4K |
| 74018 | <1% | 66 | $3K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 361 | $3K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 64 | $3K |
| 36415 | Collection of venous blood by venipuncture | <1% | 5,768 | $3K |
| 87210 | <1% | 455 | $3K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 22 | $3K |
| 83655 | <1% | 216 | $3K | |
| 87807 | <1% | 122 | $3K | |
| 82948 | <1% | 1,057 | $2K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 268 | $2K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 133 | $2K |
| 87806 | <1% | 105 | $2K | |
| 84145 | <1% | 147 | $2K | |
| 73610 | <1% | 62 | $2K | |
| 86900 | <1% | 865 | $2K | |
| 86901 | <1% | 864 | $2K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,291 | $1K |
| 73030 | <1% | 32 | $1K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 173 | $1K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 103 | $1K |
| 84702 | <1% | 95 | $1K | |
| 84153 | <1% | 82 | $1K | |
| 87340 | <1% | 128 | $1K | |
| 86592 | <1% | 290 | $947.45 | |
| 82805 | <1% | 51 | $933.98 | |
| 85018 | <1% | 428 | $900.28 | |
| 82728 | <1% | 94 | $849.58 | |
| 36592 | <1% | 508 | $849.17 | |
| 82043 | <1% | 126 | $792.31 | |
| 86762 | <1% | 73 | $775.39 | |
| 72100 | <1% | 16 | $740.06 | |
| 82962 | <1% | 328 | $703.32 | |
| 73130 | <1% | 20 | $702.07 | |
| 82607 | <1% | 49 | $587.59 | |
| 85652 | <1% | 295 | $583.54 | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 115 | $579.05 |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 804 | $556.93 |
| 86618 | <1% | 15 | $543.02 | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 15 | $525.45 |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 46 | $520.43 |
| 87653 | <1% | 12 | $520.28 | |
| 86803 | <1% | 64 | $437.53 | |
| 85730 | <1% | 163 | $411.48 | |
| 83540 | <1% | 101 | $409.11 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,361 | $390.33 |
| 83550 | <1% | 74 | $384.75 | |
| 82950 | <1% | 61 | $279.92 | |
| 85007 | <1% | 111 | $258.04 | |
| 87040 | <1% | 49 | $239.14 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,379 | $235.85 |
| 96376 | <1% | 967 | $172.80 | |
| 97162 | <1% | 31 | $157.19 | |
| A0429 | Emergency ambulance ride, basic life support | <1% | 96 | $139.07 |
| 82746 | <1% | 12 | $137.34 | |
| 82550 | <1% | 17 | $120.48 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 17 | $114.04 |
| 82947 | <1% | 12 | $86.83 | |
| 87205 | <1% | 34 | $76.98 | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,236 | $62.80 |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 37 | $59.91 |
| 82150 | <1% | 14 | $56.54 | |
| 82553 | <1% | 12 | $51.96 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,686 | $51.18 |
| A0425 | Ground mileage, per statute mile | <1% | 67 | $50.66 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,617 | $38.52 |
| 82570 | <1% | 14 | $37.72 | |
| 84156 | <1% | 16 | $30.51 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 256 | $23.46 |
| G0008 | Administration of influenza virus vaccine | <1% | 13 | $17.96 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,530 | $17.91 |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 21 | $17.09 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 15 | $13.08 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,555 | $9.40 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 44 | $8.93 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 350 | $3.48 |
| A9270 | Non-covered item or service | <1% | 475 | $0.79 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 56 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 13 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 77 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 38 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 16 | $0.00 |
| Q3014 | Telehealth originating site facility fee | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialYANG, JERRY (SVP & CHIEF FINANCIAL OFFICER)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.